Hanall Biopharma Co., Ltd. (009420.KS)
| Previous Close | 34,200.00 |
| Open | 34,550.00 |
| Bid | 34,000.00 x 0 |
| Ask | 34,100.00 x 0 |
| Day's Range | 33,950.00 - 35,150.00 |
| 52 Week Range | 18,400.00 - 46,750.00 |
| Volume | |
| Avg. Volume | 590,534 |
| Market Cap | 1.721T |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).
- PR Newswire
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for first quarter 2024 and provided business updates.
- PR Newswire
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2023 and provided business updates.
